Free Trial
NASDAQ:PYXS

Pyxis Oncology (PYXS) Stock Price, News & Analysis

Pyxis Oncology logo
$1.17 -0.02 (-1.68%)
As of 12:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Pyxis Oncology Stock (NASDAQ:PYXS)

Key Stats

Today's Range
$1.15
$1.19
50-Day Range
$1.06
$1.35
52-Week Range
$0.83
$5.39
Volume
94,213 shs
Average Volume
727,845 shs
Market Capitalization
$72.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Moderate Buy

Company Overview

Pyxis Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

PYXS MarketRank™: 

Pyxis Oncology scored higher than 35% of companies evaluated by MarketBeat, and ranked 779th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pyxis Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Pyxis Oncology has only been the subject of 1 research reports in the past 90 days.

  • Read more about Pyxis Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Pyxis Oncology are expected to decrease in the coming year, from ($1.04) to ($1.29) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pyxis Oncology is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pyxis Oncology is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pyxis Oncology has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pyxis Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    14.04% of the float of Pyxis Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Pyxis Oncology has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Pyxis Oncology has recently decreased by 4.48%, indicating that investor sentiment is improving.
  • Dividend Yield

    Pyxis Oncology does not currently pay a dividend.

  • Dividend Growth

    Pyxis Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.04% of the float of Pyxis Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Pyxis Oncology has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Pyxis Oncology has recently decreased by 4.48%, indicating that investor sentiment is improving.
  • News Sentiment

    Pyxis Oncology has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Pyxis Oncology this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for PYXS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pyxis Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.60% of the stock of Pyxis Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 39.09% of the stock of Pyxis Oncology is held by institutions.

  • Read more about Pyxis Oncology's insider trading history.
Receive PYXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter.

PYXS Stock News Headlines

Pyxis Oncology Inc News (PYXS) - Investing.com
Exclusive invitation: Name your price experiment (50 spots)
This pro trading room usually costs $2,000+ per year. But for now, you name the price. Led by a former ThinkorSwim founder and staffed by 8 professionals with nearly 200 years of combined experience, this live trading room has called 389% wins in 48 hours — and now, 50 people can test-drive it and decide what it's worth.
See More Headlines

PYXS Stock Analysis - Frequently Asked Questions

Pyxis Oncology's stock was trading at $1.56 at the start of the year. Since then, PYXS stock has decreased by 25.0% and is now trading at $1.17.

Pyxis Oncology, Inc. (NASDAQ:PYXS) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.06.

Pyxis Oncology (PYXS) raised $158 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 10,500,000 shares at $14.00-$16.00 per share.

Pyxis Oncology's top institutional shareholders include Kingstone Capital Partners Texas LLC (0.05%). Insiders that own company stock include Pfizer Inc, Lara Sullivan, Pamela Ann Connealy and Jitendra Wadhane.
View institutional ownership trends
.

Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pyxis Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/15/2025
Today
7/11/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PYXS
CIK
1782223
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$13.00
Low Price Target
$5.00
Potential Upside/Downside
+669.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$77.33 million
Net Margins
N/A
Pretax Margin
-492.35%
Return on Equity
-57.49%
Return on Assets
-45.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.75
Quick Ratio
7.75

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.03 per share
Price / Book
0.58

Miscellaneous

Outstanding Shares
61,948,000
Free Float
55,382,000
Market Cap
$72.48 million
Optionable
Optionable
Beta
1.13
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:PYXS) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners